RecruitingNot ApplicableNCT04761328

Fear of Recurrence and Stopping Immunotherapy

Distress Associated With Stopping Immunotherapy of Cancer Patients


Sponsor

University of Pittsburgh

Enrollment

100 participants

Start Date

Aug 2, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

The study includes participants experiencing distress with regard to stopping immunotherapy and will utilize cognitive-behavioral therapy to reduce fear of recurrence, depression, and anxiety and improve quality of life.


Eligibility

Min Age: 21 Years

Plain Language Summary

Simplified for easier understanding

This study explores fear of cancer recurrence — the worry that cancer will come back — in patients who have finished immunotherapy treatment, and investigates how this fear affects decisions about stopping or continuing treatment. **You may be eligible if...** - You are 21 years or older - You are fluent in English - You have been diagnosed with cancer and have received immunotherapy at some point **You may NOT be eligible if...** - You are experiencing active suicidal thoughts - You are experiencing delusions or hallucinations Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALcognitive behavioral therapy

Cognitive-behavioral therapy involves changing these erroneous cognitions and beliefs through cognitive restructuring, modification of behavior, and development of alternative coping skills.


Locations(1)

UPMC Hillman Cancer Centers

Pittsburgh, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04761328


Related Trials